To further evaluate the clinical significance of CapG in breast cancer chemotherapy resistance, we assessed the level of CapG with immunohistochemistry (IHC) assay in a tissue array with a cohort of 200 primary breast cancer patients treated with chemotherapy (Figure 2A). This evidence concerns the gene CAPG and breast cancer.